Equities

Morepen Laboratories Ltd

MOREPENLAB:NSI

Morepen Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)86.29
  • Today's Change2.69 / 3.22%
  • Shares traded11.10m
  • 1 Year change+135.12%
  • Beta1.4810
Data delayed at least 15 minutes, as of Sep 20 2024 10:46 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Febuxostat, Montelukast (Oral), Montelukast (Chewable), among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen 49W Room Air Purifier with HEPA Filter, Dr. Morepen VP06 Breathe Free Vaporizer, Dr. Morepen CN06 Compressor Nebulizer and Dr. Morepen ST03 Dual Head Stethoscope, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.

  • Revenue in INR (TTM)17.45bn
  • Net income in INR1.18bn
  • Incorporated1984
  • Employees1.62k
  • Location
    Morepen Laboratories LtdVillage Malkumajra, Nalagarh Road,BaddiGURGAON 122016IndiaIND
  • Phone+91 1 244892000
  • Fax+91 1 123722422
  • Websitehttp://www.morepen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Dishman Carbogen Amcis Ltd24.16bn-2.48bn28.62bn1.13k----165.731.18-15.81-15.81154.06--------21,344,260.00---0.3986---0.488879.3073.83-10.27-1.54---0.7216----8.414.91-414.93---0.3175--
SMS Pharmaceuticals Ltd7.38bn569.64m30.22bn1.20k52.89--33.964.096.756.7587.48--------6,168,549.00--5.43--7.3330.1233.307.697.87--4.21--6.1735.868.81805.824.478.419.86
Solara Active Pharma Sciences Ltd13.00bn-5.61bn31.68bn2.16k------2.44-143.75-143.75334.17--------6,030,149.00---2.44---3.8437.3441.16-43.17-4.49---1.57-----10.73-1.45-2,458.12---4.81--
Indoco Remedies Ltd18.22bn766.90m34.06bn5.93k44.80--19.561.878.258.25178.33--------3,072,462.00--6.88--9.8568.6165.594.106.93--2.95--14.028.9113.41-30.78--34.5437.97
Jeena Sikho Lifecare Ltd-100.00bn-100.00bn34.42bn1.23k--108.86----------12.72------------------------0.8228--0.2681--43.84--77.37------
RPG Life Sciences Limited6.00bn923.20m34.94bn1.27k37.84--31.635.8355.8255.82362.60--------4,721,969.00--16.07--21.7768.4262.9915.3911.99--220.43--29.2713.5012.0129.6051.9828.6046.14
Gufic BioSciences Ltd8.14bn863.69m40.16bn1.45k46.04--38.824.938.708.7081.95--------5,624,707.00--11.46--19.2152.3945.7910.6010.46--8.09--1.3116.8018.128.0731.4653.8314.87
SeQuent Scientific Ltd14.27bn54.87m43.00bn1.20k807.64--55.353.010.21370.213757.18--------11,939,190.00--1.09--1.7645.3841.970.99021.18--0.9009--35.06-3.605.6870.40--6.96--
Innova Captab Ltd11.42bn1.06bn44.28bn--32.66--35.643.8823.6923.69236.62------------10.82--18.3833.3825.189.308.04--8.89----16.7224.9038.8436.55104.14--
Unichem Laboratories Ltd17.28bn-605.50m45.11bn3.19k----86.352.61-8.59-8.59245.15--------5,410,587.00---1.67---2.0362.0056.18-3.50-3.99--0.1401----26.947.6465.15---35.00--
Morepen Laboratories Ltd17.45bn1.18bn45.91bn1.62k36.26--30.682.632.312.3134.26--------10,749,300.00--7.90--13.3437.8633.346.775.49--33.34--0.0019.2517.08148.6327.2247.03--
Hikal Ltd18.03bn677.82m46.42bn2.06k68.52--24.502.575.495.49145.97--------8,749,879.00--5.07--7.5153.0646.783.765.86--2.45--12.19-11.792.34-11.20-7.559.720.00
Aarti Drugs Ltd24.23bn1.57bn47.68bn1.06k30.36--22.801.9717.0817.08263.82--------22,770,740.00--9.73--15.7834.3222.236.488.25--7.28-----6.9010.133.0713.8224.96--
Supriya Lifescience Ltd5.99bn1.35bn49.03bn448.0036.26--32.318.1916.8016.8074.42--------13,370,000.00--19.08--24.0462.7557.1222.5824.71--92.47--2.8823.7415.4732.5624.7583.79--
Aarti Pharmalabs Ltd19.50bn2.25bn59.31bn1.63k26.32--19.673.0424.8624.86215.17--------11,983,730.00--------44.20--11.55----18.55-----4.76--12.10------
Data as of Sep 20 2024. Currency figures normalised to Morepen Laboratories Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

1.35%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 05 Sep 20246.35m1.16%
Dimensional Fund Advisors Ltd.as of 30 Jun 2024552.13k0.10%
SSgA Funds Management, Inc.as of 05 Sep 2024471.40k0.09%
DFA Australia Ltd.as of 31 Jul 202420.48k0.00%
American Century Investment Management, Inc.as of 05 Sep 20248.81k0.00%
Motilal Oswal Asset Management Co. Ltd.as of 31 Aug 20244.40k0.00%
More ▼
Data from 30 Jun 2024 - 31 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.